Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics

Contributed by: Business Wire

Logo

Tags

Oncology

Medical Devices

Health

Other Health

Radiology

Biotechnology

Novo Nordisk

More Like This

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Vect-Horus Strengthens its Scientific Advisory Board with the Appointment of Pr. Xavier Declèves

PR Newswire associated0

Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology

PR Newswire associated0

Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

ACCESSWIRE associated0

HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies

SK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedside